Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
Publication year range
1.
Cardiovasc Drugs Ther ; 35(2): 205-214, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-32557011

RESUMEN

Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). COVID-19 significantly affects multiple systems including the cardiovascular system. Most importantly, in addition to the direct injury from the virus per se, the subsequent cytokine storm, an overproduction of immune cells and their activating compounds, causes devastating damage. To date, emerging anti-SARS-CoV-2 treatments are warranted to control epidemics. Several candidate drugs have been screened and are currently under investigation. These primarily include antiviral regimens and immunomodulatory regimens. However, beyond the anti-SARS-CoV-2 effects, these drugs may also have risks to the cardiovascular system, especially altering cardiac conduction. Herein, we review the cardiovascular risks of potential anti-COVID-19 drugs.


Asunto(s)
Antivirales/farmacología , Tratamiento Farmacológico de COVID-19 , COVID-19 , Cardiotoxicidad/prevención & control , Sistema Cardiovascular/efectos de los fármacos , Factores Inmunológicos/farmacología , SARS-CoV-2/efectos de los fármacos , COVID-19/inmunología , Humanos , Medición de Riesgo
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda